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Abstract 
The organometallic complex coenzyme B12 (adenosyl cobalamin, AdoCbl) is not only an 
essential coenzyme in many biochemical reactions of most if not all living organisms but has 
lately been shown to play a crucial role in the gene-regulation of B12 related genes. As a 
consequence, coenzyme B12 has been a target of intense research. However, investigations of 
AdoCbl have often been hampered due to its high light-sensitivity leading to decomposition 
of the compound within a few seconds. Here, we describe a strategy to synthesize more light 
stable coenzyme B12 analogs, which show similar steric properties as adenosyl cobalamin. 
The synthesis, structural characterization as well as the pH dependent "base-on/base-off" 
behavior of cyanide bridged vitamin B12 conjugates with either a cis-[(NH3)2Pt]2+ or an 
[enPt]2+ moiety, leading to cis-[(NH3)2PtCl-vitB12]+ (1) and [enPtCl-vitB12]+ (2) are reported. 
Subsequent reaction of cis-[(NH3)2PtCl-vitB12]+ with the model nucleobase 9-methyladenine 
leads to the corresponding adduct, where the adenine moiety is coordinated to the Pt2+ center 
either via N1 or N7. This compound is light stable and harbors the adenine moiety in the same 
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1. Introduction 
 Coenzyme B12 (AdoCbl) is the structurally most complex of all known vitamins and is 
essential for most or even all living organisms as a cofactor for numerous enzymatic reactions 
in the metabolic pathways [1]. Only recently it was discovered, that coenzyme B12 does not 
only interact with proteins but can also bind specifically and with high affinity to conserved 
RNA sequences found in the 5'-untranslated region of mRNA [2]. This high affinity binding 
between a small molecule and its target RNA sequence, the so-called riboswitch, exhibits an 
alternative pathway for the regulation of gene-expression [3-6]. Binding is highly specific and 
the adenine moiety of adenosyl cobalamin seems to play an important role in recognition of 
the coenzyme by the RNA. In the case of the two best studied B12-responding riboswitches, 
the so-called btuB-leading sequence of Escherichia coli and Salmonella typhimurium 
(encoding for a B12-transport protein) and the leading-sequence of the cob-operon of S. 
typhimurium (encoding for different proteins of the B12 biosynthetic pathway) coenzyme B12 
is the derivative contributing to gene regulation [7-9]: Binding of B12 derivatives is rather 
tight with dissociation constants of around 0.3 µM (AdoCbl), 3 µM (MeCbl) and 30 µM for 
vitamin B12, while aquo-cobalamin has no effect on the gene regulation [7]. However, 
coenzyme B12 is known to be highly light-sensitive and to decompose within a few seconds 
[10]. Due to this fact, coenzyme B12 is difficult to handle in many biochemical applications 
and experiments such as the research on the B12-responding riboswitches [8]. In the following, 
we describe our efforts towards the synthesis of more light-stable AdoCbl derivatives while 
preserving the crucial structural features of this complex. 
 Recently, a method was described by Mundwiler et al. to derivatize the cyanide ligand of 
vitB12 by coordinating a cis-[(NH3)2PtCl]+ unit to this ligand and subsequently to attach a 
guanine moiety to the Pt2+ center [11]. Comparison of the crystal structures of the cis-
[(NH3)2Pt(9-MeGua)-vitB12]2+ (9-MeGua = 9-methylguanine) adduct [11] and of 5’-
desoxyadenosylcobalamin [12] show close structural similarities. The Co-Pt distance of 
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around 5 Å found in the adduct compares well with the Co-C1' distance of 5.05 Å in 5’-
desoxyadenosylcobalamin, as do the orientations of the nucleobases, positioned parallel to the 
corrin ring. This finding opens the possibility to synthesize more light stable AdoCbl analogs 
by coordinating an adenine moiety to the Pt2+ center of such cyano-bridged vitB12 derivatives.  
 Thus, in the present context we are focusing on the preparation and characterization of cis-
[(NH3)2PtCl]+ [11] and newly also the [enPtCl]+ adducts of vitamin B12 and their subsequent 
reaction with the model nucleobase 9-methyladenine. In the re-determined crystal structure of 
the Cisplatin adduct all anions could be localized, and this structure will be compared in the 
following to the new structure of the [enPtCl]+ adduct of vitB12. We further investigated the 
"base-on/base-off" behavior of the two complexes and compared it with vitamin B12 as well 
as with coenzyme B12. Reaction of cis-[(NH3)2PtCl-vitB12]+ with 9-methyladenine leads to 
two adenine adducts, in which the nucleobase is coordinated to the Pt2+ center either through 
its N1 or N7 position. This model compound is light-stable, but compares structurally very 
well to adenosyl cobalamin with respect to the position of the adenine base.  
 
2. Experimental Section 
2.1 Starting Materials 
 9-Methyladenine [13,14], cis-(NH3)2PtCl2 [15,16] and cis-[(NH3)2PtCl-vitB12]CF3CO2 (1) 
[11] were synthesized according to the literature. Chemicals used were purchased from 
Calbiochem, San Diego, USA (vitamin B12 (99.6%)), Alfa Aesar, Karlsruhe, Germany 
(dichloro(ethylenediamine)platinum(II) (59.82% Pt)), Fluka, Buchs, Switzerland or ACROS 
Organics, Geel, Belgium, and were used without further purification.  
 
2.2 Instrumentation 
 HPLC analyses were performed on a Hitachi Elite LaChrom system equipped with a L-
2400 UV detector and a Nucleodur C18 Gravity RP column (5 µm particle size, 110 Å pore 
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size, 250x4 mm, Macherey-Nagel). The HPLC-solvents used were 0.1% trifluoro acetic acid 
in H2O (A) and methanol (B). The preparative HPLC separation was performed on a Varian 
Prostar system equipped with two Prostar 215 pumps, a Prostar 320 UV/Vis detector and a 
Nucleosil C-18ec RP column (7 µm particle size, 100 Å pore size, 250x21 mm, 14 mL min−1 
flow rate, or 250x40 mm, 40 mL min−1 flow rate, Macherey-Nagel). ESI mass spectra were 
measured on a Waters Q-TOF Ultima API spectrometer, while the LC-MS was performed 
using ESI detection on a AQUA Thermo Finnigan spectrometer and a Sorbax C-18 column (3 
µM pore size, 150x21 mm). UV/Vis spectra were recorded at 25 °C on a Varian Cary 500 
spectrometer. IR spectra were recorded on a Perkin-Elmer Spectrum BX spectrometer in KBr 
pellets. All NMR spectra were recorded at 298 K with 3-(trimethylsilyl)-1-propanesulfonic 
acid sodium salt as a reference; 1H-NMR and 13C-NMR spectra were recorded on a Bruker 
AV 700 MHz spectrometer with a CP-TXI cryoprobe, [1H,1H]-COSY and [13C,1H]-HSQC 
measurements on a Bruker AV 600 MHz spectrometer equipped with a CP-TCI triple 
resonance cryoprobe and 31P-NMR and 195Pt-NMR spectra on a Bruker DRX 500 MHz 
spectrometer with a 5 mm BBO probehead.  
 
2.3 Preparations 
[enPtCl-vitB12]CF3CO2 · 15.8 H2O · 1.1 (CH3)2CO (2): A solution of enPtCl2 (72 mg, 0.22 
mmol) and AgNO3 (37 mg, 0.22 mmol) in H2O (8 mL) was stirred under N2 atmosphere and 
in the dark for 2.5 h at 35 °C. The precipitated AgCl was removed by centrifugation (10 min, 
6000 rpm) and washed with H2O (4 mL). Vitamin B12 (300 mg, 0.22 mmol) was added to the 
combined solutions of [enPtCl(H2O)]+ (12 mL) and stirred under N2 atmosphere and 
exclusion of light for 17.5 h at 50 °C. The reaction was followed by analytical HPLC on a 
reversed phase column (gradient: 5 min at 75% 0.1% trifluoro acetic acid and 25% methanol, 
then linear to 100% methanol within 24.5 min, 0.5 mL min−1 flow rate). The solvent was 
removed in vacuo, and the crude product purified by preparative HPLC on a C-18 reversed 
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phase column (gradient: linear from 100% A to 20% B in 5 min, linear to 65% B in 40 min 
and then linear to 100% B within 5 min). The peak from 18 to 23 min was collected, the 
solvent removed in vacuo and the red solid dissolved in ca. 3 mL H2O. Lyophilization of this 
product fraction gave 340 mg of 2 as a purple powder (0.196 mmol, 89%). Recrystallization 
by vapor diffusion of acetone into an aqueous solution yielded the complex with CF3CO2– as 
anion, as well as 1.1 acetone and 15.8 water molecules per asymmetric unit. 1H NMR (D2O, 
600 MHz): δ = 7.28 (s, 1H, H-B7), 7.07 (s, 1H, H-B2), 6.50 (s, 1H, H-B4), 6.35 (d, J = 2.8 
Hz, 1H, H-R1), 6.08 (s, 1H, H-10), 4.71 (ddd, J = 8.5, 8.5, 4.2 Hz, H-R3), 4.35-4.27 (m, 3H, 
H-3, H-176, H-R2), 4.10 (d, J = 10.4 Hz, 1H, H-19), 4.05 (d, J = 3.9 Hz, 1H, H-R4), 3.92 (d, 
J = 12.0 Hz, 1H, Ha-R5), 3.75 (dd, J = 12.8, 3.8 Hz, 1H, Hb-R5), 3.61 (d, J = 14.2 Hz, 1H, H-
175), 3.53 (dd, J = 11.0, 5.3 Hz, 1H, H-8), 3.35 (d, J = 10.2 Hz, 1H, H-13), all other peaks 
were not specifically assigned. 13C NMR (D2O, 150.94 MHz) δ = 180.4 (C-4), 179.1 (C-16), 
177.8, 177.5, 176.8, 176.7, 175.6, 175.3, 174.6, 174.5, 173.8 (9C, C-9, C-11, C-22, C-33, C-
72, C-83, C-133, C-173, C-182), 165.8 (C-14), 165.3 (C-6), 141.5 (C-B2), 136.2 (C-B9), 
135.0, 133.0 (2C, C-B5, C-B6), 129.5 (C-B8), 116.0 (C-B4), 111.4 (C-B7), 107.2 (C-5), 
103.8 (C-15), 94.6 (C-10), 86.9 (C-R1), 84.9 (C-1), 81.8 (d, J = 32.7 Hz, C- R4), 74.9 (C-19), 
72.8 (d, J = 13.3 Hz, C-R2), 72.6 (d, J = 25.2 Hz, C-R3), 68.5 (t, J = 25.3 Hz, C-176), 60.1 
(C-R5), 59.1 (C-17), 56.0 (C-3), 55.1 (C-8), 53.4 (C-13), 50.9 (C-7), 47.99, 47.97, 47.96 (3C, 
C-12, C11en, C12en), 46.97 (C-2), 45.0 (q, J = 16.0, C-175), 43.3, 43.0 (2C, C-21, C-71), 38.8 
(C-18), 34.6, 34.2, 32.4, 32.1, 31.3, 31.23, 31.20, 27.7, 25.8, 25.7 (10C, C-12B,C-31, C-32, 
C-81, C-82, C-131, C-132, C-171, C-172, C-181), 19.67, 19.00, 18.95, 18.83, 18.76, 18.74, 
16.46, 16.10, 15.27, 14.88 (10C, C-B10, C-B11, C-1A, C-2A, C-7A, C-12A, C-17B, C-51, C-
151, C-177. 31P-NMR (D2O, 202.5 MHz): δ = –0.701 ppm. 195Pt-NMR (D2O, 107.5 MHz ): δ 
= –2700 ppm. ESI-MS: m/z: 823.26 [M]2+. IR (KBr): ν = 2195 cm–1 (CN). UV/Vis (H2O): 
λ(logε) = 250.0 (4.1), 279.0 (3.8), 362.0 (4.05), 515.0 (3.5), 550.0 (3.5 mol L–1 cm–1). 
 cis-[(NH3)2Pt(9-MeAde)-vitB12](CF3CO2)2 (3): A suspension of 1 (20 mg, 11.7 µmol) and 
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9-methyladenine (88 mg, 0.59 mmol) in H2O (1 mL) was stirred under N2 atmosphere and 
exclusion of light for 1 week at 45 °C. Analytical HPLC on a reversed phase column 
(gradient: 5 min at 75% 0.1% trifluoro acetic acid and 25% methanol, then linear to 100% 
methanol within 24.5 min, 0.5 mL min−1 flow rate) showed the formation of two new peaks at 
5.6 and 7 min next to the peaks of the reagent and of vitamin B12 deriving from 
decomposition. The solvent was removed in vacuo, and the crude product purified by 
preparative HPLC on a C-18 reversed phase column (gradient: linear from 100% A to 20% B 
in 5 min, linear to 65% B in 40 min and then linear to 100% B within 5 min). Only a small 
fraction (at 21.6-23 min) of a broad peak was collected. Lyophilization of the product fraction 
gave 3 in 49% yield (11 mg, 5.8 µmol, yield calculated based on two CF3CO2– anions) as a 
mixture of two isomers (N1 and N7 coordinated to the Pt2+ center), which could not be 
separated so far. 1H NMR (D2O, 700 MHz, only resonances of the coordinated 9-MeAde are 
given): δ = 8.37, 8.36 (2 s, 1H for each isomer, Ade-H2/H8, see also text), 8.22, 8.20 (2s, 1H 
for each isomer, Ade-H2/H8, see also text), 3.85, 3.83 (2 s, 3 H for each isomer, Ade-C9H3). 
195Pt-NMR (D2O, 107.5 MHz): δ = –2573.5 ppm. LC-MS: m/z: 865.1[M-4H]2+. 
 
2.4 X-ray crystallography 
Crystal data for compounds 1 and 2 were collected on a STOE IPDS system using 
graphite monochromated Mo Kα radiation (λ = 0.7107 Å) and a low-temperature device at 
183 K. For data reduction and the numerical absorption corrections, the program X-RED 32 
(Version 1.01, STOE & Cie GmbH, 2001) was used. The structures were solved by 
conventional Patterson methods and subsequent Fourier syntheses and refined by full-matrix 
least squares for F2 using the SHELX program [17]. The positions of all non-hydrogen atoms 
were deduced from difference Fourier maps and refined anisotropically with the exceptions 
described below. In compound 1, most of the partially occupied water molecules were refined 
isotropically and were either given a common U(eq) value to allow free refinement of the site 
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occupation factors, or the latter were fixed at appropriate values and the U(eq) values refined. 
Part of the acetone molecules, which are all fully occupied, as well as part of the second 
counter ion were only refined isotropically, as well as O134 of one molecule as it would turn 
into "non-positive refined". Hydrogen atoms were placed in calculated positions and refined 
with isotropic displacement parameters, while no hydrogen atoms were added to the acetone, 
the water molecules, as well as to the ribose O5R. The entire {enPtNCl} moiety in compound 
2 is disordered over two positions with occupancy factors of 75% and 25%, respectively. 
Atoms N1CN_A, N12_A, C11_A, and C12_A of the lower occupied {enPtNCl} moiety could 
only be refined isotropically or they would result in a "non-positive refined" state. One of the 
amide groups of the corrin ring, consisting of C83, N84, O84, is likewise disorderd over two 
different positions of 75% and 25% occupancy each. Again, the lower occupied group is kept 
isotropically. All partially occupied water molecules were refined isotropically with a 
common U(eq) value and the site occupation factors was left to refine freely. The counter ions 
is spread over two positions, again with occupancies of 75% and 25%, respectively, and was 
refined isotropically. One acetone molecule (60%, anisotropic refinement) shares its position 
with two water molecules (10%, and 40%), the other acetone (50%, isotropic refinement) is 
best described as sharing space with three water molecules (25% each). Hydrogen atoms were 
included in calculated positions and refined with isotropic displacement parameters. No 
hydrogen atoms were added to the 25% occupied {enPtNCl} moiety, the 25% occupied amide 
group, as well as to the acetone and water molecules. Crystallographic data and details of 
refinement are reported in Table 1. 
 
3. Results and Discussion 
3.1 Characterization of [enPtCl-vitB12]CF3CO2 · 15.8 H2O · 1.1 (CH3)2CO (2):  
Complex 2 was prepared in analogy to the preparation of 1 (see also Scheme 1) [11]. The 
reaction of enPtCl2 with one equivalent of silver nitrate led to the aqua species 
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[enPtCl(H2O)]+ as an intermediate, which was not isolated but subsequently reacted with 
vitamin B12 to give the [enPtCl-vitB12]+ adduct 2 in 89% yield. 
The reaction between [enPtCl(H2O)]+ and vitamin B12 was followed by HPLC. After 
stirring of the reaction mixture at 50 °C for 17.5 h, the ratio between a new emerging peak at 
7.7 min retention time and the peak of substrate vitamin B12 at 13.8 min was found to be 
around 80:20. Product 2 was isolated by preparative HPLC. The ESI-MS spectrum of 
[enPtCl-vitB12]+ (2) indicated a peak at m/z = 823.26 corresponding to the mass of the doubly 
charged product. This signal together with peaks of lower intensity at 822.27, 822.76, 823.77, 
824.26 and 824.77 display the typical isotope pattern expected for the presence of one 
platinum atom. IR spectroscopy shows a clear shift of the νCN of 2 towards higher 
wavenumbers with respect to vitamin B12 (from 2134 to 2195 cm–1), a typical finding caused 
by the electron-pulling effect of the platinum(II) coordination (Fig. 1) [18]. 
Based on earlier studies [19,20] and with the aid of [1H,13C]-HSQC and a [1H,1H]-COSY-
NMR experiments, most 13C-NMR and 1H-NMR signals with shifts downfield from 3 ppm 
could be assigned. The most characteristic signals for B12-derivatives are the 5 peaks between 
7.3 and 6 ppm belonging to H2, H4 and H7 of the 5,6-dimethylbenzimidazole (DMB) moiety, 
H1R of the ribose as well as H10 of the corrin ring (Fig. 2a). These 1H signals are very similar 
to the ones observed for cis-[(NH3)2PtCl-vitB12]+ (1) [11]. The 13C-NMR signals of 2 are in 
good correlation with vitamin B12 [19] showing only small deviations between 0.02 and 0.62 
ppm. The largest deviations are observed at C7, C8 and C72 of the corrin ring, at C4B, C8B 
and C9B of the 5,6-dimethylbenzimidazole, as well as at C2R of the sugar- and C175 of the 
aminopropanol moieties (Fig. 3a). Changes in chemical shift at the DMB ligand imply that the 
Pt2+ coordination influences the coordination properties of the cobalt center across the 
octahedron in the axial position. Chemical shifts assigned to ring B, i.e. of C7, C8, and C71, 
are probably influenced due to the positioning of the en-ligand above, which might be fixed 
also in solution by a hydrogen bond of one ammine proton at N12 to O73 located at ring B, as 
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observed in the crystal structure (see also Fig. 4a). The two carbon atoms of the 
ethylenediamine ligand gave signals at around 48 ppm and showed a strong correlation to a 
triplet at 2.36 ppm in the [1H,13C]-HSQC arising from the corresponding ethylene protons. 
 
3.2 Crystal structures of cis-[(NH3)2PtCl-vitB12]CF3CO2 · 12.4 H2O · 2.5 (CH3)2CO (1) and 
[enPtCl-vitB12]CF3CO2 · 15.8 H2O · 1.1 (CH3)2CO (2):  
 The crystal structure of compound 1 has been solved previously, but lacked one of the two 
CF3CO2– anions most likely due to disorder [11]. We now obtained crystals of both, 1 and 2, 
by vapor diffusion of acetone into an aqueous solution of the compounds and were able to 
improve the structure of compound 1 in such a way, that both anions plus additional acetone 
and water molecules could be refined. 
 Complex 1 crystallizes in space group P1 with two complex molecules per asymmetric 
unit. Compound 2 (monoclinic C2) shows only one platinum complex in the asymmetric unit, 
but the axial CN-enPtCl unit is distributed over two positions with occupancies of 75 and 25 
% (see also Tables 1 and 2 as well as Fig. 3b). 
 Overall, the two complexes 1 and 2 are very similar and the coordination geometries of 
the cobalt centers are virtually identical. The lengths of the axial bonds to the cyanide and the 
benzimidazole ligands in 1 and 2 also correspond quite well (Table 2) to the ones in free 
vitamin B12: The Co-CCN distances in 1, 2 and vitB12 are identical within their error limits 
(1.858(12) Å in vitB12 [21]) as it is also true for the Co-N3B bond (2.011(10) Å in vitB12 
[21]).  
 The platinum(II) centers show an almost perfect square planar geometry. Interestingly, the 
smallest Pt-N distance is in all cases the one to the cyanide ligand, although this is the bond 
most easiest broken, as the occasional occurrence of free vitB12 in the HPLC experiments 
shows (see also Section 3.4). In addition, it should be mentioned that both, the cis-
[(NH3)2PtCl]+ and the [enPtCl]+ moieties, are located accordingly above the corrin plane, 
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being "fixed" by an intramolecular hydrogen bond between one am(m)ine proton and O73 of 
the B12 unit (Fig. 4a). 
 
3.3 "Base-on/base-off" behavior of 1 and 2:  
 The "base-on/base-off" behavior of coenzyme B12, i.e. the intramolecular equilibrium of 
the coordination or release of the DMB moiety from the axial position at the cobalt center is 
of great biological importance. Coenzyme B12 exists predominately in the "base-on" form 
with the dimethylbenzimidazole moiety coordinated via N3 to the cobalt atom. However, 
recent crystallographic studies have shown that coenzyme B12 and its analogs can switch 
under certain conditions from the "base-on" to a "base-off/His-on" form when binding to their 
receptor protein by replacing the DMB ligand with the imidazole unit of a proteinogenic 
histidine residue [22-24]. 
 In the absence of protein, the state of the intramolecular "base-on/base-off" equilibrium is 
dependent on the pH value of the solution. Upon acidification, protonation of the N3 position 
of the DMB ligands occurs causing the predominance of the "base-off" form at acidic pH 
[25]. This conformational change can be followed either by circular dichroism (CD) or by 
UV/Vis spectroscopy due to a change of the absorbance maxima from around 520 nm in the 
"base-on" form to around 460 in the "base-off" form [26-29]. AdoCbl has a pKbase-off = 3.67 
[30] which is much more basic compared to vitamin B12, which has a pKbase-off = 0.1 [31]. 
This difference may be explained by the much stronger electron donating effect of the ribose 
coordination compared to the anionic cyanide ligand. It is obvious, that the ease with which 
the DMB ligand is replaced by another coordinating moiety plays an important role in terms 
of binding capacity to proteins and other biomolecular complexes.  
 We investigated the "base-on/base-off" behavior of 1 and 2 by titrating a 50 µM solutions 
of each vitamin B12 derivative with HNO3 in the pH range from 10 to –0.3 (Fig. 5). Nearly no 
changes in the UV/Vis spectra were found between pH 10 and 2 and a clear dominance of the 
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"base-on" form was found down to pH 1 in both cases. The spectrum of 2 still shows an 
excess of the "base-on" form at pH 0.5. As can be seen in Fig. 5, at pH 0, the characteristic 
"base-on" bands around 514 and 550 nm get broader and consequently lower in absorption. At 
pH values around –0.3 increasing amounts of the "base-off" form are present as can be seen 
from the emerging new maximum at around 500 nm. Compound 1 already starts to change to 
the "base-off" form at pH 0.2. Therefore, the pKbase-off of the two B12 derivatives 1 and 2 are 
comparable to the one of vitamin B12. This is not surprising as the coordination of the 
platinum(II) center to the cyanide ligand will not increase the electron density on the cobalt 
center but instead rather diminish it. 
 
3.4 Characterization of cis-[(NH3)2Pt(9-MeAde)-vitB12]2+ (3): 
 In order to synthesize coenzyme B12 analogs, we added 9-methyladenine (9-MeAde) to 
the cis-[(NH3)2PtCl-vitB12]+ adduct (Scheme 1). As the superimposition of the structures of 
AdoCbl and complex 2 in Fig. 4b shows, the relative positions of the adenine N9 and the 
chloride ligand in 2 (which is replaced by a coordinating ring nitrogen of an adenine 
derivative) are in perfect agreement. The agreement will be still quite good when the longer 
Pt2+-Cl bond (2.3 Å) is replaced by the shorter Pt2+-N bond (typically 2.0 Å). Because of the 
corresponding positions of the adenine bases in the two compounds, it is well feasible that an 
adenine adduct of 1 or 2 consitutes a very good analogue of AdoCbl in terms of binding 
properties towards proteins, RNAs or other molecules. 
 It is well known that cis- and trans-platinum(II) centers can coordinate to all unsubstituted 
positions of nucleobase moieties with the N7 positions of purines and the N1 position of 
adenine being the predominant binding sites at neutral pH [32-40]. Indeed, it has recently 
been shown that 1 can coordinate to 9-methylguanine or 2'-deoxyguanosine through the N7 
position under replacement of the second chloride-ligand [11]. In case of coordination to 
adenine derivatives the situation is a little more complicated as N1 and N7 compete for 
Inorganica Chimica Acta  S. Gallo, E. Freisinger, R. K. O. Sigel      13/23 
 
binding [40]. Usually, N1 coordination can be suppressed to a large part by acidifying the 
reaction solution to a pH below 3 thereby blocking this site by protonation [41,42]. However, 
compounds 1 and 2 proved to be sensitive to acidic conditions as, e.g. storage overnight at 4 
°C in 0.1% trifluoro acetic acid let to breakage of the cyanide-Pt bond in both complexes. 
Partial decomposition of the two complexes was also observed when 1 and 2 were treated 
with one equivalent of AgNO3 to replace the chloro ligand with a water molecule in order to 
activate the Pt2+ center for coordination to the adenine moiety. Therefore, we reacted complex 
1 with a large excess of 50 equivalents of 9-methyladenine in water without addition of any 
acid. The reaction was followed by HPLC and after one week of stirring at 50 °C, two new 
peaks between 5 and 7 min retention time (next to the peaks of the reagent and of free vitamin 
B12 deriving from decomposition) were detected. Compound 3 was isolated from the main 
peak at 6.5 min. Characterization of this product by analytical HPLC showed only one peak. 
In addition, analysis of 3 by LC-MS gave one single peak at m/z = 865.1, which corresponds 
to the mass of the twofold charged product cis-[(NH3)2Pt(9-MeAde)-vitB12]2+ (3) lacking four 
hydrogen atoms. Taken together this is a clear indication that indeed the chloride ligand at the 
Cisplatin entity is replaced by 9-methyladenine, yielding the single product 3.  
 A 1H-NMR of 3 shows the aromatic protons of the 9-methyladenine moiety at 8.37 ppm 
and 8.21 ppm, which is further highfield compared to cis-[(NH3)2Pt(9-MeAde)Cl]+ (8.35 ppm 
for H2 and 8.57 ppm for H8) [42] and further downfield to free 9-MeAde (8.15 ppm for H2 
and 8.00 ppm for H8) [42]. The strong downfield shift confirms the Cisplatin bridged species 
3. The same is true for the resonance of the C9-H3 methyl group (see also Experimental 
Section). All signals assigned to the 9-methyladenine ligand of 3 are split in about a 1:1 ratio 
(Fig. 2b) indicating that not one but two species are present. One possibility could be that 
there is a hindered rotation around the Co-CN-Pt axis thus "fixing" the adenine ligand in two 
different positions and giving two conformational isomers. However, this seems unlikely 
because the 9-MeAde lies about 5 Å above the corrin plane, i.e. a distance which is by far 
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larger than stacking distances of typically around 3.3 – 3.4 Å. In addition, in case of the 9-
ethylguanine adduct also no splitting of the aromatic H8 signal was observed [11]. A much 
more likely explanation – and the one we favor – is the presence of the N1 and N7 
coordinated isomers, whose formation one would actually expect based on the reaction 
conditions in the absence of acid. Comparison with the chemical shifts of free 9-MeAde and 
its Cisplatin complex mentioned above, implies that the two aromatic signals more downfield 
at about 8.47 ppm belong to H8 and H2 of the N7 and N1 platinated species, respectively, as 
Pt2+ induces a strong downfield shift due to its electron pulling properties. Consequently, the 
signals at around 8.32 ppm belong to H2 of the N7-platinated and H8 of the N1-platinated 
species 3. Unfortunately, a separation of such two isomeric forms was not successful so far 
due to their very similar properties. Nevertheless, we detected no decomposition of the cis-
[(NH3)2Pt(9-MeAde)-vitB12]2+ (3) complex in the NMR tube over several days. Considering 
that after the initial isolation of 3, this complex was always handled under normal daylight 
conditions, this fact demonstrates the great potential of such more light stable cobalamin 
derivatives.  
 
3.5 Summary and conclusion 
 Here we have presented a synthetic pathway towards the synthesis of light stable 
derivatives of adenosyl cobalamin with an adenine moiety covalently attached above the 
corrin plane. The intermediates cis-[(NH3)2PtCl-vitB12]CF3CO2 · 12.4 H2O · 2.5 (CH3)2CO (1) 
and [enPtCl-vitB12]CF3CO2 · 15.8 H2O · 1.1 (CH3)2CO (2) have been characterized by X-ray 
crystallography, 1H- and 13C-NMR spectroscopy, as well as by their intramolecular acid-base 
dependent "base-on/base-off" equilibria examined with UV/Vis spectroscopy. We showed 
that the coordination of the cis-[(NH3)2PtCl]+ or [enPtCl]+ entity to vitamin B12 has little 
influence on this equilibrium, which is also expected to be the case with compound 3.  
 The 9-methyladenine adduct 3 could only be synthesized as a presumable mixture of two 
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isomeric forms, i.e. the N1 and N7 coordinated complexes. Nevertheless, to the best of our 
knowledge, this is the first time that such a light-stable adenosyl cobalamin derivative has 
been synthesized where the adenine base is not only directly linked to the cobalt-corrin 
system but should also have the same distance above the corrin plane as in AdoCbl. It should 
be noted however, that in AdoCbl, the adenine base is flipped, i.e. the N7 is in the position of 
the N9 position and vice versa, as N9 is bound to the ribose C1' atom (Fig. 4b). This means 
that together with the relative rigidity of 3, a different hydrogen bonding pattern of this model 
compound is expected. Nevertheless, this differenc might not be crucial because the 
predominant interaction of the adenosine ligand when binding to a protein or a RNA 
riboswitch might very well be purelly based on stacking interactions with aromatic amino acid 
side chains or nucleobases, as the adenine base is known to have excellent stacking properties 
[43-46]. The correct distance of about 5 Å between the 9-methyladenine and the corrin ring in 
3 ensures that stacking interactions with the host molecule would still be possible (Fig. 4b).  
 To summarize, compound 3 represents a model system for AdoCol to (i) investigate the 
replacement of the benzimidazole moiety by a host molecule side chain, and (ii) to 
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Table 1. Crystallographic data for compounds 1 and 2. 
 1 2 
Formula C145H267.6Cl2Co2F6N32O61.8P2Pt2 C70.3H134.2ClCoF3N16O32.9PPt
Formula weight 4203.19 2107.30 
Crystal system triclinic monoclinic 
Space group P1 C2 
a / Å 16.922(3) 33.832(7) 
b / Å 17.298(3) 17.282(3) 
c / Å 18.101(3) 16.995(3) 
α / ° 112.77(2) 90.00 
β / ° 98.47(2) 100.13(3) 
γ / ° 91.69(2) 90.00 
V / Å3  4810(1) 9782(3) 
Z 1 4 
Dcalc / g cm–3 1.451 1.431 
µ(Mo Kα) / mm–1 1.758 1.731 
F(000) 2184 4372 
Crystal size / mm 0.32 × 0.10 × 0.10 0.35 × 0.15 × 0.10 
Temperature / K 183(2) 183(2) 
Radiation / Å Mo Kα (0.71069) Mo Kα (0.71069) 
θmin, θmax / ° 2.30, 24.71 1.87, 25.81 
Dataset -19:19; -20:20; -21:21 -41:41; -21:21; -20:20 
Tot., uniq. data, Rint 60944, 30817, 0.078 34604, 18674, 0.045 
Observed data [I > 2 σ(I)], Npar 27849, 1605 14824, 1177 
R, wR2, S [I > 2σ(I)]a 0.0564, 0.1421, 1.075 0.0482 0.1076, 0.980 
Max. and av. shift/error 0.00, 0.00 0.00, 0.00 
Min. and max. resd. dens. [e Å–3] 2.81, -1.44 0.61, -1.14 
a R1 = Σ||Fo| – |Fc|| / Σ||Fo|, wR2 = [Σw(Fo2 – Fc2)2 / Σw(Fo2)2]1/2. 
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Table 2. Selected bond and hydrogen bond lengths (Å) as well as angles (°) for compounds 1 
and 2. 
 1 (mol a) 1 (mol b) 2a 
 Pt-Cl  2.305(3)  2.310(3)  2.318(3) 
 Pt-N11  2.041(8)  2.032(7)  2.036(6) 
 Pt-N12  2.061(9)  2.029(8)  2.026(8) 
 Pt-NCN  1.977(8)  1.962(8)  1.960(8) 
 Co-CCN  1.875(9)  1.849(8)  1.870(5) 
 Co-N3B  2.020(8)  2.046(7)  2.025(4) 
    
 N11-Pt-NCN  177.7(4)  179.3(4)  176.8(5) 
 N12-Pt-Cl  177.6(3)  178.0(2)  177.2(2) 
 N3B-Co-CCN  179.2(4)  179.3(4)  178.3(2) 
    
 N12···O73  2.852(12)  2.910(10)  2.872(8) 
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Figure Legends 
Fig. 1. Section of the IR-spectra of vitamin B12 (top), cis-[(NH3)2PtCl-vitB12]+ (1) (bottom) 
and [enPtCl-vitB12]+ (2) (middle). The νCN bands of both Pt2+ adducts (1, 2199 cm−1; 2, 2195 
cm−1) are shifted towards higher wavenumbers compared to vitamin B12 (2134 cm–1) being a 
clear indication for a bridging cyanide ligand [18]. 
 
Fig. 2. 1H-NMR spectra of (a) [enPtCl-vitB12]+ (2) and (b) of the cis-[(NH3)2Pt(9-MeA)-
vitB12]2+ adduct (3). Signals of the benzimidazole ligand (O), the ribose H1R (Q), and H10 
(V) of the corrin ring are indicated. The three signals belonging to the 9-MeAde moiety are 
split (see insert in b), implying the presence of both N7 and N1 coordinated 9-methyladenine 
(see also text). The more downfield signals (◊) are assigned to H2 and H8 of the N1- and N7-
platinated species, respectively, whereas the corresponding H8 and H2 further away from the 
respective platination site give resonances around 8.32 ppm (). The methylgroup (O) of the 
9-methyladenine ligand is also indicated.  
 
Fig. 3. Numbering scheme and crystal structure of [enPtCl-vitB12]CF3CO2 · 15.8 H2O · 1.1 
(CH3)2CO (2). (a) Numbering scheme of [enPtCl-vitB12]+ as used in this study, corresponding 
to the one introduced in ref. [1].  (b) Ortep plot of 2 showing ellipsoids of 50% probability 
together with the atom numbering scheme.   
 
Fig. 4. Superimposition of structures of B12 derivatives. (a) Overlap of the crystal structures 
of 1 and 2, illustrating that these two complexes virtually have the same conformation. In both 
structures, the am(m)ine ligands form an intramolecular hydrogen bond to O73 of a corrin 
ring side chain of the vitB12 entity. (b) Stereoview of the superimposition of the crystal 
structures of coenzyme B12 (grey, CCDC DADCBL) [47] and complex 2 (black). It can be 
well seen that the N9 position of the adenine base occupies the exact same position as the 
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chloride ligand in 2 therefore underlining the validity of the here presented model system. The 
positions of the chloride ligand (a, b) and the adenine N9 (b) are highlighted by black and 
grey spheres, respectively. The side chains at the corrin ring are omitted for clarity. 
 
Fig. 5. Section of the UV/Vis spectra of [enPtCl-vitB12]+ (2) at different pH values ranging 
from pH 8 to –0.3 . The "base-on" form with a maximum at 550 nm is solely present down to 
pH 0.5. At pH values below zero the dimethylbenzimidazole moiety becomes protonated and 
the "base-off" form absorbing at 465 nm starts to gain importance. Titration points: pH 8, 
black line; pH 2, dark grey line; pH 1, grey line; pH 0.5, black dotted line; pH 0.2, dark grey 
dotted line; pH 0, grey dotted line; pH –0.3, light grey dotted line. 
 
Scheme 1. Formation of the cis- or enPt-bridged vitamin B12 derivatives and consecutive 
reaction with 9-methyladenine to give a mixture of N7 and N1 coordinated adduct(3).  
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